These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis. Legány N; Toldi G; Distler JH; Beyer C; Szalay B; Kovács L; Vásárhelyi B; Balog A Clin Chem Lab Med; 2015 Oct; 53(11):1799-805. PubMed ID: 25894644 [TBL] [Abstract][Full Text] [Related]
10. Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis. Butt S; Jeppesen JL; Iversen LV; Fenger M; Eugen-Olsen J; Andersson C; Jacobsen S PLoS One; 2021; 16(2):e0247256. PubMed ID: 33617568 [TBL] [Abstract][Full Text] [Related]
11. The diagnostic value of soluble urokinase-type plasminogen activator receptor (suPAR) for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine. Scharrenberg JS; Yagdiran A; Brinkmann J; Brune M; Siewe J; Jung N; Mahabir E J Orthop Surg Res; 2019 Nov; 14(1):367. PubMed ID: 31727136 [TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease. Kolho KL; Valtonen E; Rintamäki H; Savilahti E Scand J Gastroenterol; 2012 Sep; 47(8-9):951-5. PubMed ID: 22746351 [TBL] [Abstract][Full Text] [Related]
13. Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy. Xiao Y; Luo H; Zhou B; Dai X; Huang J; Duan L; You Y; Zhang W; Zhao H; Xie Y; Zhou Y; Ning W; Li T; Liu S; Zhu H; Xie X; Jiang Y; Wu S; He W; Li Y Rheumatol Int; 2017 Apr; 37(4):585-592. PubMed ID: 27878344 [TBL] [Abstract][Full Text] [Related]
14. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954 [TBL] [Abstract][Full Text] [Related]
15. The Association of uPA, uPAR, and suPAR System with Inflammation and Joint Damage in Rheumatoid Arthritis: suPAR as a Biomarker in the Light of a Personalized Medicine Perspective. Benucci M; Damiani A; Russo E; Guiducci S; Li Gobbi F; Fusi P; Grossi V; Amedei A; Manfredi M; Infantino M J Pers Med; 2022 Dec; 12(12):. PubMed ID: 36556207 [TBL] [Abstract][Full Text] [Related]
16. Profile of common inflammatory markers in treatment-naïve patients with systemic rheumatic diseases. Kim MJ; Lee EB; Song YW; Park JK Clin Rheumatol; 2020 Oct; 39(10):2899-2906. PubMed ID: 32314175 [TBL] [Abstract][Full Text] [Related]
17. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease. Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033 [TBL] [Abstract][Full Text] [Related]
18. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627 [TBL] [Abstract][Full Text] [Related]